Skip to main
ALKS

Alkermes (ALKS) Stock Forecast & Price Target

Alkermes (ALKS) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 43%
Hold 21%
Sell 0%
Strong Sell 0%

Bulls say

Alkermes PLC is poised for continued revenue growth through 2030, primarily driven by lower royalties from Invega and the acquisition of Lumryz, which is expected to generate significant annualized sales of approximately $265-$275 million by 2025. Furthermore, the company's pipeline includes promising products such as alixorexton, which has demonstrated encouraging efficacy data, enhancing the potential for long-term growth beyond 2025. The acquisition of Lumryz not only offers immediate profitability but also strengthens Alkermes’ commercial opportunities without adversely impacting its balance sheet, contributing to an overall positive outlook for the company.

Bears say

Alkermes PLC faces a negative outlook primarily due to anticipated sales stagnation of its lead product, Lumryz, which is expected to peak at approximately $600 million in 2030 before experiencing annual declines associated with the loss of exclusivity in 2037. Risks such as the potential failure of the orexin program, erosion of its royalty business, and the effectiveness of its proprietary products add further pressure on future earnings, compounded by a significant reliance on Medicaid revenue amid regulatory uncertainties. Additionally, increasing competition from other orexin 2 receptor agonists and shifts in patient preferences may hinder Lumryz's market growth, suggesting a potential mismatch between current share pricing and the company’s long-term cash flow outlook.

Alkermes (ALKS) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 43% recommend Buy, 21% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alkermes (ALKS) Forecast

Analysts have given Alkermes (ALKS) a Buy based on their latest research and market trends.

According to 14 analysts, Alkermes (ALKS) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alkermes (ALKS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.